Spots Global Cancer Trial Database for sintilimab 200 mg, intravenously (iv) every 3 weeks(q3w)
Every month we try and update this database with for sintilimab 200 mg, intravenously (iv) every 3 weeks(q3w) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer | NCT05216237 | Gastric Cancer Chemotherapy Immunotherapy | Sintilimab 200 ... | 18 Years - 75 Years | Affiliated Hospital of Qinghai University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
